Literature DB >> 25932845

Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk.

Danielle S Abbott1, Natasha L Hezelgrave, Paul T Seed, Jane E Norman, Anna L David, Phillip R Bennett, Joanna C Girling, Manju Chandirimani, Sarah J Stock, Jenny Carter, Ruth Cate, James Kurtzman, Rachel M Tribe, Andrew H Shennan.   

Abstract

OBJECTIVE: To evaluate the diagnostic accuracy of cervicovaginal fluid quantitative fetal fibronectin, measured by a bedside analyzer, to predict spontaneous preterm birth before 34 weeks of gestation.
METHODS: We conducted a prospective masked observational cohort study of cervicovaginal fluid quantitative fetal fibronectin concentration in asymptomatic women at high risk of spontaneous preterm birth (n=1,448; 22-27 6/7 weeks of gestation) measured using a rapid bedside analyzer. The routine qualitative result (positive-negative) was made available to clinicians at the time of testing, but the quantitative result remained blinded until after delivery.
RESULTS: Spontaneous preterm birth (less than 34 weeks of gestation) increased from 2.7%, 11.0%, 14.9%, 33.9%, and 47.6% with increasing concentration of fetal fibronectin (less than 10, 10-49, 50-199, 200-499, and 500 ng/mL or greater, respectively). A threshold of 200 ng/mL had a positive predictive value of 37.7 (95% confidence interval [CI] 26.9-49.4) with specificity 96% (95% CI 95.3-97.3). Women with a fetal fibronectin concentration of less than 10 ng/mL had a very low risk of spontaneous preterm birth at less than 34 weeks of gestation (2.7%), no higher than the background spontaneous preterm birth rate of the general hospital population (3.3%). The quantitative fetal fibronectin test predicted birth at less than 34 weeks of gestation with an area under the curve (AUC) of 0.78 (95% CI 0.73-0.84) compared with the qualitative test AUC 0.68 (95% CI 0.63-0.73). Quantitative fetal fibronectin discriminated risk of spontaneous preterm birth at less than 34 weeks of gestation among women with a short cervix (less than 25 mm); 9.5% delivered prematurely less than 10 ng/mL compared with 55.1% greater than 200 ng/mL (P<.001). DISCUSSION: Alternative risk thresholds (less than 10 ng/mL and greater than 200 ng/mL) improve accuracy when using quantitative fetal fibronectin measurements to define risk of spontaneous preterm birth. This is particularly relevant for asymptomatic women with a short cervix. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25932845     DOI: 10.1097/AOG.0000000000000754

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  20 in total

1.  A high concentration of fetal fibronectin in cervical secretions increases the risk of intra-amniotic infection and inflammation in patients with preterm labor and intact membranes.

Authors:  Kyung Joon Oh; Roberto Romero; Jee Yoon Park; Jihyun Kang; Joon-Seok Hong; Bo Hyun Yoon
Journal:  J Perinat Med       Date:  2019-04-24       Impact factor: 1.901

2.  Multimode smartphone biosensing: the transmission, reflection, and intensity spectral (TRI)-analyzer.

Authors:  Kenneth D Long; Elizabeth V Woodburn; Huy M Le; Utsav K Shah; Steven S Lumetta; Brian T Cunningham
Journal:  Lab Chip       Date:  2017-09-26       Impact factor: 6.799

Review 3.  Screening for spontaneous preterm birth and resultant therapies to reduce neonatal morbidity and mortality: A review.

Authors:  Angelica V Glover; Tracy A Manuck
Journal:  Semin Fetal Neonatal Med       Date:  2017-12-09       Impact factor: 3.926

4.  Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women.

Authors:  M Sean Esplin; Michal A Elovitz; Jay D Iams; Corette B Parker; Ronald J Wapner; William A Grobman; Hyagriv N Simhan; Deborah A Wing; David M Haas; Robert M Silver; Matthew K Hoffman; Alan M Peaceman; Steve N Caritis; Samuel Parry; Pathik Wadhwa; Tatiana Foroud; Brian M Mercer; Shannon M Hunter; George R Saade; Uma M Reddy
Journal:  JAMA       Date:  2017-03-14       Impact factor: 56.272

5.  Timing of antenatal corticosteroids in relation to clinical indication.

Authors:  Jessica Smith; Kellie E Murphy; Sarah D McDonald; Elizabeth Asztalos; Amir Aviram; Stefania Ronzoni; Elad Mei-Dan; Arthur Zaltz; Jon Barrett; Nir Melamed
Journal:  Arch Gynecol Obstet       Date:  2022-01-18       Impact factor: 2.493

6.  Quantitative fetal fibronectin and cervical length in symptomatic women: results from a prospective blinded cohort study.

Authors:  Lisa D Levine; Katheryne L Downes; Julie A Romero; Hope Pappas; Michal A Elovitz
Journal:  J Matern Fetal Neonatal Med       Date:  2018-05-15

7.  Quantitative fetal fibronectin to predict spontaneous preterm birth: a review.

Authors:  Natasha L Hezelgrave; Andrew H Shennan
Journal:  Womens Health (Lond)       Date:  2015-12-11

8.  Evaluating the use of the QUiPP app and its impact on the management of threatened preterm labour: A cluster randomised trial.

Authors:  Helena A Watson; Naomi Carlisle; Paul T Seed; Jenny Carter; Katy Kuhrt; Rachel M Tribe; Andrew H Shennan
Journal:  PLoS Med       Date:  2021-07-06       Impact factor: 11.069

9.  Use of metabolomics for the identification and validation of clinical biomarkers for preterm birth: Preterm SAMBA.

Authors:  Jose G Cecatti; Renato T Souza; Karolina Sulek; Maria L Costa; Louise C Kenny; Lesley M McCowan; Rodolfo C Pacagnella; Silas G Villas-Boas; Jussara Mayrink; Renato Passini; Kleber G Franchini; Philip N Baker
Journal:  BMC Pregnancy Childbirth       Date:  2016-08-08       Impact factor: 3.007

10.  Maternal Whole Blood Gene Expression at 18 and 28 Weeks of Gestation Associated with Spontaneous Preterm Birth in Asymptomatic Women.

Authors:  Yujing J Heng; Craig E Pennell; Sheila W McDonald; Angela E Vinturache; Jingxiong Xu; Mary W F Lee; Laurent Briollais; Andrew W Lyon; Donna M Slater; Alan D Bocking; Lawrence de Koning; David M Olson; Siobhan M Dolan; Suzanne C Tough; Stephen J Lye
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.